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OVERVIEW AND AIMS 
Obesity is one of the biggest public health problemsof the 21st century1. The World Health Organi-
zation (WHO) defines obesity when body mass index
(BMI) is greater than or equal to 30 Kg/m2 1,2. The last
estimates affirm that obesity has more than doubled
since 1980, with nearly 30-70% of European adults be-
ing overweight and 10-30% being obese1. Weight ex-
cess confers a higher risk of diabetes, cardiovascular di -
sease and cancer (including endometrial cancer) and
besides being a public health problem, contributing to 
elevated costs in health, it imposes new challenges in
the treatment of many diseases2.  Metabolic changes in
obesity and a higher body mass index may lead to re-
duced effectiveness of many drugs in which hormonal
contraceptives are an example, but nevertheless is still
controversial3,4. 
Heavy menstrual bleeding (HMB), also named
menorrhagia, is defined as excessive menstrual blood
loss which interferes with the woman’s physical, emo-
tional, social and material quality of life5,6. It affects 
4-51.6% of women. However, the real prevalence is 
unknown, because the studies available are very hete -
rogeneous in what concerns the population and the cri-
teria (personal perception of excessive menstrual blood
loss (MBL) or objective as MBL >80mL) that were
used5. HMB increases with age, being more frequent in
the perimenopausal period5,6. Other risk factors for
HMB are the presence of uterine fibroids, blood disor-
ders, endometriosis, adenomyosis, smoking and high
alcohol consumption5.Obesity has been associated with
dysfunctional uterine bleeding, secondary amenorrhea
and polycystic ovary syndrome2,7,8. 
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Abstract
Objective:We aimed to identify if there was any difference in Levonorgestrel-releasing intrauterine system (LNG-IUS)
efficacy or weight gain when used in heavy menstrual bleeding (HMB) treatment, between obese and non-obese women.
Population and methods: This was a case-controlled retrospective study undertaken between 2002-2007. 194 women
with HMB were treated with LNG-IUS and stratified into two groups accordingly with body mass index (BMI): Obese
Group – BMI ≥ 30 (n=53) and Non-obese Group – BMI < 30 (n=141). Age, weight, days of spotting and days of menses
were analyzed at 1, 3 and 6 months after insertion and then annually until 2 years. Analytic parameters of anemia
(hemoglobin, serum ferritin, mean corpuscular volume) were reviewed at pre-insertion, at 6 months and then annually un-
til 2 years. 
Results: During the 2-year follow-up there was a similar improvement in two groups regarding duration of menses, spot-
ting and in analytic parameters of anemia. A statistically significant improvement was observed in obese group after 2 years
of treatment regarding analytic parameters of anemia and menstrual characteristics, without weight gain.  
Conclusion: In obese women, the LNG-IUS is an effective treatment for heavy menstrual bleeding, without being asso-
ciated to weight gain. 
Keywords: Levonorgestrel-releasing intrauterine system; Obesity; Body mass index; Heavy menstrual bleeding; Anemia.
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Medical treatment of HMB includes the levo -
norgestrel-releasing intrauterine system (LNG-IUS),
oral and injectable progestins, danazol, non-steroidal
anti-inflammatories and tranexamic acid2,5-9. Surgical
alternatives are available when medical treatment has
failed3. Hysterectomy and endometrial ablation are the
sur gical solutions available, however they are associa te d
with peri-operative and long-term surgical risks3-9.  
The LNG-IUS is a T-shaped contraceptive device
with a reservoir containing 52 mg of levonorgestrel. It
delivers 20 mcg a day and maintains its efficacy for at
least 5 years9,10. One of its effects is endometrial sup-
pression, without ovulation inhibition5-10. The LNG-
-IUS has proved to be one of the most effective medi -
cal treatments for HMB, by reducing the MBL in 79-
-87%5,6,9,10. Apart from reducing the MBL it has shown
to improve anemia analytic parameters that result from
HMB5,6,9,10. Some previous studies related to the con-
traceptive effect of LNG-IUS support its use in obese
women, however it is associated with a slight increase
in weight3.
The aim of our study was to compare the use of
LNG-IUS in the treatment of HMB between obese
and non-obese women. We wished to ascertain if there
were any differences in menstrual characteristics, ane-
mia analytic parameters and weight between the two
groups of women. 
STUDY DESIGN, POPULATION AND METHODS
This was a retrospective, case-control study, performed
between 2002 and 2007.  
Using a clinical database, we identified all women
in reproductive age, aged ≥ 18 years, with HMB who
underwent LNG-IUS insertion, between 1st January
2002 and 31 December 2007. We chose this time
frame because during this period, at our institution,
there was a specific medical appointment destined to
follow-up women with HMB who were treated with
LNG-IUS. HMB was defined as excessive menstrual
blood loss that interfered with women’s quality of life.
The etiology of HMB was classified according to
PALM-COEIN classification (polyp; adenomyosis;
leiomyoma; malignancy and hyperplasia; coagulopa-
thy; ovulatory dysfunction; endometrial; iatrogenic;
and not yet classified)11. Women who chose LNG-IUS
as a way of treatment for their HMB were scheduled
for that medical appointment, where the insertion and
a protocol of follow-up were performed. The LNG-
-IUS was inserted within 7 days of the onset of mens -
truation. The follow-up protocol approved at our ins -
titution included an appointment at the LNG-IUS in-
sertion clinic, at 1, 3 and 6 months and then annually
until discharge from the hospital or LNG-IUS re-
moval. 
The WHO’s criterion for anemia in non-pregnant
adult women is an hemoglobin value of less than 12.0 g/dL,
and was the value admitted for diagnosis of anemia.12
The anemia parameters, such as hemoglobin, ferritin
and mean globular values, were recorded in all patients
and not only in patients with anemia diagnosis. 
We considered two groups: in obese group were in-
cluded women who had a first appointment mean body
index (BMI) ≥30 Kg/m2 and in non-obese group wo -
men who had BMI <30 Kg/m2. The parameters ana-
lyzed were: age, number of days of spotting, number of
days of menses and weight at month 1, 3 and 6 and
then annually until the second year. The anemia pa-
rameters (hemoglobin, ferritin and mean globular volu -
me) were analyzed at insertion, at month 6 and then
annually for 2 years. We also analyzed the rate of ex-
pulsion, reasons for removal and the number of hys-
terectomies performed. Women who didn’t have the
register of BMI were excluded from analysis. We con-
sidered a 2-year interval for analysis because there was
very little data available after year 2. Besides compa ring
the different parameters between the two groups, we
compared in the obese group the different parameters
at year 2 with pre-insertion values, in order to verify if
LNG-IUS is effective in the treatment of HMB in this
group. We did not compare the same values in the non-
-obese group because LNG-IUS efficacy is already well
established13. The data were collected by consul ting
clinical files. 
The statistical analyses were performed with SPSS
statistical software (version 14.0; SPSS Inc, Chicago,
IL). The Wilcoxon test was applied to dependent varia -
bles, the Mann-Whitney test was applied to indepen-
dent samples and the Chi-square test was 
applied to categorical variables. Probability values of
<0.05 were considered statistically significant. 
RESULTS
Subject disposition and demographic 
characteristics
Out of the 282 LNG-IUS inserted for HMB treat-
ment, 194 women met the inclusion criteria and were
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divided in two groups according to their initial BMI,
Figure 1. 
The mean age of participants was similar in both
groups (obese group: 44.17±5.4, non-obese group:
43.52±5.0, p=0.434). 
The etiology of HMB was similar in both groups,
being adenomyosis the most frequent diagnosis, 52.8%
and 47.5% in obese and non-obese groups respective-
ly, followed by leiomyomas, 26.4% and 33.3% in obese
and non-obese groups respectively. Unexpectedly,
polyps were only present in non obese women, how-
ever, 70% of these were present in women with BMI
in the overweight range (25-30 Kg/m2). Others diag-
nosis included in the PALM-COEIN classification
had no expression in this series and were excluded from
analysis.  The frequencies of HMB etiology is pre-
sented in Table I. 
Menstrual characteristics
Analyzing the medical profiles, we could not obtain
the baseline days of menses and days of spotting. How-
ever, when we analyzed the days of menses during the
2 years after insertion we observed that the days of
menses and days of spotting progressively decreased in
both groups, in a similar way (Table II). When we
compared the mean days of menses and spotting at
month 1 with year 2 only in the obese group, we ob-
served a significant decline (Table V). 
Anemia analytic parameters 
At the baseline, the mean hemoglobin levels were
simi lar in both groups, 12.36 g/dL and 12.44g/dL, in
obese and non-obese women respectively (Table III);
36.7% had anemia in obese group compared to 33.8%
in non-obese group, p=0.729. During the two years of
follow-up, the mean values of hemoglobin registered
a progressive rise in both groups (Table III). When we
analyzed the difference between the values of
hemoglobin at year 2 with pre-insertion values, the
main gain of hemoglobin was 1.02 and 3.55, in obese
and non obese group respectively, being the difference
between the two groups not statistically significant,
p=0.128 (Table III). After 2 years there were no values
of Hb below 12g/dL in both groups. In the obese
group there was a significant gain in hemoglobin after
two years, rising from 12.36g/dL to 13.66g/dL,
p=0.004 (Table V).
With respect to ferritin, we observed a similar pro-
gressive rise in ferritin mean values in both groups, ri -
sing from 29.01 and 23.30 at baseline to 71.87 and
55.74 after 2 years in obese and non-obese group res -
pectively (Table III). The mean gain in ferritin in obese
group after 2 years was 45.21, p=0.001 (Table V). 
The mean corpuscular volume (MCV) values at the
baseline were similar in both groups, 83.04 fL and
84.79 fL, in the obese and non-obese women respecti -
TABLE I. ETIOLOGY OF HBM ACCORDING TO PALM-COEIN CLASSIFICATION
Obese Non obese P- value
Adenomyosis 28 / 52.8% 67 / 47.5% 0.438
Leiomyomas 14 / 26.4% 47/ 33.4% 0.388
Ovulatory Disfunction 9 / 17% 13 /9.2% 0.117
Polyps 0 / 0% 10 / 7.1% 0.048
Not classified 2/ 3.8% 4 / 2.8% 0.720
Total 53 / 100% 141 / 100%
Legend: HMB, heavy menstrual bleeding; PALM-COEIN classification: polyp; adenomyosis; leiomyoma; malignancy and hyperplasia;
coagulopathy; ovulatory dysfunction; endometrial; iatrogenic; and not yet classified. Malignancy and hyperplasia, coagulopathy and iatrogenic
categories were excluded from analysis
Excluded: 88 women without initial BMI register194 Women
282 Women to whom aLNG-IUS was inserted formenorrhagia treatment
Obese group: BMI ≥ 30 Kg/m2N= 53 (27.3%) Non-obese group: BMI < 30 Kg/m2N= 141 (72.7%)
Excluded: 88 women without 
initial BMI register
194 Women
282 Women to whom a
LNG-IUS was inserted for
menorrhagia treatment
Obese group: 
BMI ≥ 30 Kg/m2
N= 53 (27.3%)
Non-obese group: 
BMI < 30 Kg/m2
N= 141 (72.7%)
FIGURE 1. Population of the study
vely. During the two years, a rise in MCV values in
both groups was observed, with a mean gain of 3.04 fL
and 4.95 fL in obese and non-obese group respective-
ly (Table III). When we compared the mean value of
MCV at year 2 with the pre-insertion mean value in
the obese group, we observed a significant rise, being
83.04fL at pre-insertion and 85.55fL after 2 years,
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p=0.006 (Table V). 
Weight gain
At the LNG-IUS insertion, the mean weight in the
obese group was 87.16 Kg as opposed to the non-obese
group where the mean weight was 64.62Kg, p<0.001.
When we analyzed the weight gain during the 2 years
TABLE II. MEAN CHANGE IN DAYS OF MENSES AND DAYS OF SPOTTING DURING THE TWO YEARS AFTER LNG-IUS
INSERTION
Obese Non-obese
n Mean±SD n Mean±SD p value
Days of menses Month 1 41 4.17±4.83 105 4.23±464 .740
Month 3 37 3.46±3.73 85 3.58±4.14 1
Month 6 39 3.44±4.94 93 2.65±2.98 .933
Year 1 30 2.10±2.67 83 2.02±2.80 .778
Year 2 19 2.26±3.25 50 2.26±5.25 .423
Year 2 – Month 1 21 -0.67±4.45 50 -1.60±6.31 .239
Days of spotting Month1 41 9.24±9.68 105 10.58±9.65 .390
Month 3 36 3.33±5.138 86 6.06±8.20 .100
Month 6 39 3.49±7.56 91 2.98±4.45 .124
Year 1 30 1.50±5.42 83 1.33±3.03 .366
Year 2 22 0.32±0.95 58 1.21±3.59 .335
Year 2 – Month 1 21 -10.5±9.65 51 -10.0±1.20 .985
SD: standard deviation.
TABLE III. MEAN CHANGE IN ANALYTIC PARAMETERS OF ANEMIA 
Obese Non-obese
n Mean±SD n Mean±SD p value
Hemoglobin Pre-insertion 49 12.36±1.69 139 12.44±1.48 .963
Month6 36 13.04±1.32 77 13.20±1.27 .344
Year 1 31 13.61±1.02 84 13.50±1.24 .845
Year 2 19 13.66±0.92 49 15.94±14.34 .301
Year 2 – Pre-insertion 18 1.02±1.37 49 3.55±14.36 .128
Ferritin Pre-insertion 46 29.01±38.39 126 23.30±24.07 .460
Month 6 33 32.71±31.91 69 31.87±40.35 .723
Year1 29 44.35±34.14 80 34.22±31.68 .133
Year2 18 71.87±72.70 41 55.74±40.32 .397
Year 2 – Pre-insertion 18 45.21±56.06 41 34.75±33.62 .850
MCV Pre-insertion 50 83.04±8.17 136 84.79±9.76 .065
Month 6 35 82.72±13.16 75 85.42±9.66 .252
Year 1 31 83.86±12.80 81 87.25±10.28 .013*
Year 2 19 85.55±10.25 48 89.85±3.72 .023*
Year 2 – Pre-insertion 19 3.04±14.26 47 4.95±6.44 .848
MCV: Mean corpuscular volume; SD: standard deviation, *= p<0.05, statistically significant
after LNG-IUS insertion, we observed that there was
almost no increase in weight in either group, registe -
ring even a slight decrease (Table IV).  When we ana -
lyzed the obese group only, the mean weight at pre-in-
sertion was 87.16Kg vs 86.03Kg 2 years after LNG-
-IUS insertion, p=0.146 (Table V). 
Follow-up 
During the two years considered in the study there was
a substantial decrease in the number of women in each
group. At year 2 there were only 41.5% women in the
obese group and 41.1% in the non-obese group when
compared to baseline. During the two years there were
10 LNG-IUS expulsions in obese group (18.9%) and
11 in non-obese group (7.8%), p=0.037. Obesity was
associated with a 2.75 higher risk of LNG-IUS ex-
pulsion when compared to non obese women, (IC 95%
1.09-6.92). In the obese group 13 (18.8%) women
were submitted to hysterectomy, compared to 16
(11.4%) women in the non-obese group, all as a con-
sequence of HMB persistence, p=0.014. The relative
risk of hysterectomy in the obese group was 2.80, (IC
95%, 1.26-6.26). Eight (15.1%) women were discharge
before the 2 years follow-up, all being asymptomatic as
well as 39 (27.7%) in non-obese group, all being re-
ferred to their family doctor. Seventeen women
(12.1%) were lost to follow-up in non-obese group.
One woman (1.9%) in the obese group requested
LNG-IUS removal, compared to 5 women (3.6%) in
non-obese group, p=0.564.
DISCUSSION 
Many papers concerning contraception mention that
LNG-IUS can be effective in obese women. Howe ver,
few studies were performed in order to evaluate if
LNG-IUS is effective in HMB treatment in selected
obese women3,5,6. Our study wishes to evaluate if there
are any differences between obese and non-obese
women when using LNG-IUS as a treatment option
for HMB. 
During the two years of follow-up there were no
differences between either group concerning the days
of menses and the days of spotting. In both groups
there was a progressive decrease in the days of menses,
which didn’t achieve a statistical difference between
groups, p=0.239. Nevertheless, the decrease in days of
menses and spotting in the obese group after two years
of treatment was statistically significant (p=0.043 and
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TABLE VI. AVERAGE WEIGHT GAIN DURING THE 2 YEARS AFTER LNG-IUS INSERTION
Obese Non-obese
n Mean±SD n Mean±SD p value
Weight Gain Month 1 41 0.37±1.18 96 0.15±4.93 .939
Month 3 36 -0.35±3.05 82 1.08±3.50 .070
Month 6 34 0.15±2.95 75 0.65±2.92 .839
Year 1 29 -0.60±6.16 70 0.39±3.39 .865
Year 2 14 1.14±3.15 33 -0.21±2.95 .216
: Standard deviation. *= p<0.05, statistically significant
TABLE V. AVERAGE CHANGE IN DIFFERENT 
PARAMETERS BEFORE OR DURING THE FIRST MONTH
AFTER LNG-IUS INSERTION IN OBESE WOMEN WITH
MENORRHAGIA
Obese women
Parameters n Mean±SD P value
Days of Month 1 41 4.17±4.83 .043*
menses Year 2 22 2.26±3.25
Days of Month 1 42 9.24±9.68 <0.001*
spotting Year 2 22 0.32±0.95
Hemoglobin Pre-insertion 49 12.36±1.69 .004*
Year 2 19 13.66±0.92
Ferritin Pre-insertion 41 29.01±38.39 .001*
Year 2 9 71.87±72.70
MCV Pre-insertion 45 83.04±8.17 .006*
Year 2 11 85.55±10.25
Weight Pre-insertion 53 87.16±12.02 .146
Year 2 14 86.03±11.54
MCV: mean corpuscular volume, SD: Standard deviation, 
*= p<0.05, statistically significant 
p<0.001, respectively) which supports LNG-IUS effi -
cacy in HMB treatment in the obese group concer -
ning menstrual characteristics. 
Anemia parameters, such as hemoglobin, mean
globular volume and ferritin levels improved similarly
in both groups during the two years (Table III). Such
finding is consistent with the literature, where LNG-
-IUS has demonstrated to raise hemoglobin, mean
globular volume and ferritin levels in women with
HMB5,6,10,14-17. When we compared the anemia pa-
rameters in the obese group, between the baseline and
year 2 we found a statistically significant improvement
in all parameters (Table V). Once again LNG-IUS
seems to be effective in improving anemia parameters
in obese women treated for HMB. 
Weight gain is sometimes a concern when a con-
traceptive is initiated and in some cases a reason for
early discontinuation. However, in 2011 Lopez et al
in a Cochrane review could find only a little evidence
in weight gain when progestin-only contraceptives
were used, where weight gain was less than 2 Kgs and
up to 12 months19. Other studies demonstrated that
there was no significant weight gain associated with
LNG-IUS and one study revealed that LNG-IUS in
long term users has been associated with a small in-
crease in weight that was equivalent to the weight gain
associated with increasing age4,18,20. In our study, the
weight gain in both groups didn’t reach a statistical dif-
ference during the 2 years (weight gain in obese group
after 2 years: 1.14, vs -0.21 in non obese group, p=
0.216). When we compared the initial and final weight
in the obese group we concluded that there wasn’t a
significant change (initial weight 87.16 vs 86.03 after
2 years, p=0.146). Besides small data, it suggests that
LNG-IUS does not provoke weight gain, even in
obese women. 
LNG-IUS expulsion is the most common cause for
failure and occurs in about 5% of users when randomi -
zed controlled trials are considered and in about 9.9%
when observational studies are taken into account10,15.
LNG-IUS expulsion occurs mainly in the first year 
after insertion and is more frequent in nulliparous
women, women with severe dysmenorrhea and when
inserted immediately after postpartum or post-abor-
tion10. In our study, the expulsion rate was 18.9% in
the obese group and 7.8% in the non-obese group. The
rate of expulsion in the non-obese group is in accor-
dance with the expulsion rate when observational stu -
dies are considered. However, the expulsion rate in
obese women greatly exceeds the expulsion rate in the
litera ture. In our study, obesity was associated to a re -
lative risk of 2.75 of LNG-IUS expulsion. A possible
explanation for this finding can be a more difficult
LNG-IUS insertion in obese women that leads to an
incorrect insertion and higher rate of expulsion. How -
 ever, new prospective larger studies should be con-
ducted to verify if LNG-IUS expulsion rate in obese
women is superior when compared with non-obese
women. 
One limitation of our study is the small data and
large number of women who were lost to follow-up.
Many of these women abandoned the hospital
appoint ment after being discharged to their family
physician, all being asymptomatic (15.1% in obese
group and 27.7% in non-obese group). However,
LNG-IUS wasn’t successful enough to avoid hys-
terectomy in some women, which accounted 18.8% in
obese group and 11.4% in non-obese, p=0.014, all be-
cause of HMB maintenance. More studies are nee ded,
preferably prospective, including more obese women
and stratifying effectiveness with the grade of obesity.  
To summarize, the LNG-IUS seems to be an ef-
fective option in HMB treatment in obese women, re-
ducing the number of days of menses and spotting and
improving anemia analytic parameters, such as
hemoglobin, ferritin and mean globular volume. Be-
sides its beneficial effects in HMB treatment, it is also
important that LNG-IUS insertion in obese women
doesn’t seem to be associated with weight gain. How-
ever, new prospective, larger studies are needed to
prove these findings.  
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